PPM1E proteins and nucleic acids as targets for neurodegenerative diseases

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 8574861
APP PUB NO 20100261182A1
SERIAL NO

12739878

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

1. Use of

    (v) a gene coding for a protein phosphatase 1 E having SEQ ID NO:1 or SEQ ID NO:2, and/or(vi) a transcription product of the gene coding for a protein phosphatase 1 E having SEQ ID NO:1 or SEQ ID NO:2, and/or(vii) a translation product of the gene coding for a protein phosphatase 1 E having SEQ ID NO:1 or SEQ ID NO:2, and/or(viii) a fragment, or derivative, or variant of (i) to (iii).for identifying or for testing agents for the treatment and/or prevention of neurodegenerative diseases.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • EVOTEC AG

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Von, Der Kammer Heinz Hamburg, DE 36 100

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 May 5, 2025
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00